Inclusion Criteria:

- · Patients aged 18 years or older with a documented diagnosis of metastatic, stage
II-IV, epithelial ovarian cancer and a histological/cytological confirmation of
disease.· Patients must be oophorectomized or be post-menopausal (i.e. no menses
within the last 12 months).· Patients should have objective evidence of measurable
disease according to the modified RECIST guidelines. If no measurable disease is
present, there must be a CA 125 level of ³ 30 U/mL in combination with non-measurable
disease and/or ascites.· Patients may be designated:· First line - patients who have
either refused or did not qualify for initial therapy with standard cis- or
carboplatin + paclitaxel.· Refractory - progression while on chemotherapy, or relapse
within 12 months of final chemotherapy (with a maximum of 2 lines of chemotherapy
treatment)· Recurrent - relapse beyond 12 months of final chemotherapy (with a
maximum of 2 lines of chemotherapy treatment)· In patients having received radiation
therapy, at least 4 weeks must have passed subsequent to the cessation of the
radiation therapy, prior to the baseline assessment in this study.· Patients with
ECOG performance status of 0, 1 or 2 and a life expectancy of > 3 months.·
Patients must have adequate haematological (WBC ³ 4000/mL, neutrophils ³ 2000/mL,
platelets ³ 100,00/mL), hepatic (total bilirubin £ 1.5 x upper limit normal (ULN),
AST/ALT £ 3 x ULN)) and renal (serum creatinine < 1.5 X ULN) organ functions.·
Patients must give written informed consent signed prior to registration.

Exclusion Criteria:

- Known hypersensitivity to exemestane· Participation in another clinical study within
thirty days prior to the treatment on this study. Concurrent treatment with other
experimental drugs or anticancer therapy.· Patients with rapidly progressive disease
for which hormonal therapy may not be indicated.· Concomitant malignancies except for
adequately treated carcinoma in situ of the uterine cervix or basal or squamous cell
carcinoma of the skin. Patients with other malignancies must be disease free for at
least 5 years.· Patients with metastatic disease of the central nervous system, eg.
Paraneoplastic cerebellar degeneration, metastatic medulloblastoma, intramedullary
spinal cord involvement, etc.· Patients having received prior hormonal therapy for
ovarian cancer including tamoxifen and aromatase inhibitors.· Patients with any other
concurrent disease, which in the opinion of the Investigator, would make the patient
inappropriate for entry into this study.· Patients who are not accessible for
treatment and follow-up in scheduled hours at the participating center.